Renewcell announces intention to carry out a directed issue of new shares towards Swedish and international institutional investors and publishes its interim report Q3 2022 today, ahead of schedule

MAR

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Re:NewCell AB (publ) (“Renewcell” or the “Company”) hereby announces its intention to, based on the authorization granted by the annual general meeting held on 17 May 2022 and with deviation from the shareholders’ preferential right, carry out a directed new issue of shares corresponding to proceeds of approximately SEK 150 million (the “Directed Share Issue”), towards Swedish and international institutional investors. Renewcell has mandated Nordea Bank Abp, filial i Sverige (“Nordea”) as Sole Global Coordinator and Joint Bookrunner and Pareto Securities AB (”Pareto”) as Joint Bookrunner (Pareto together with Nordea, the “Managers”) to evaluate the conditions to carry out the Directed Share Issue through an accelerated book-building procedure, starting immediately. The Company’s largest shareholders, H&M Group and Girincubator AB (via the family affiliated Girindus Investments AB) have indicated interest to participate in the Directed Share Issue. The Directed Share Issue proceeds will mainly be used to finance operational expenses during the ramp-up and increased capital expenditures (“CAPEX”) as described below. Furthermore, Renewcell has today through a separate press release published its interim report Q3 2022, instead of 28 October 2022 as previously communicated, for the purpose of the intended capital raise.

Background
As previously communicated, Renewcell has installed a new production line at the Renewcell 1 plant in Ortviken, Sundsvall, Sweden to produce 60,000 metric tons per year of the recycled textile material Circulose®. The production line has been installed and the initial start-up process commenced 19 August 2022. As part of the start-up process, intensive work has taken place since that date, and is ongoing, to calibrate and regulate the functionality of the production line ready for the commercial production of Circulose®.
 
The start-up process of Renewcell 1 has taken longer than previously expected, causing a delay of the production ramp-up and therefore revenue generation from Renewcell 1 and an increase in CAPEX related to the prolonged start-up process of Renewcell 1. The subsequent production ramp-up to 60,000 metric tons is also expected to take longer than previously expected. This leads to an expected increase in the negative profit effect from the fourth quarter 2022 until Renewcell 1 has reached the expected production capacity of 60,000 metric tons. The expected profitability once fully ramped-up remains unchanged.
 
As a result, the Company has a funding need of approximately SEK 150 million, of which approximately SEK 100 million is required to finance the negative profit effect (operational expenses) and approximately SEK 50 million is required to finance CAPEX.
 
Due to the expected increased CAPEX of approximately SEK 50 million, the total investment for the Renewcell 1 plant in Ortviken (with capacity up to 120,000 metric tons) is now estimated to reach approximately SEK 1.45 billion (compared to the previous assessment of approximately SEK 1.40 billion).
 
The Company intends to raise capital in the form of a new share issue to meet the funding need. As a result of this new share issue, the completion of the start-up process and the production ramp-up of Renewcell 1 to 60,000 metric tons in the first stage and then to 120,000 metric tons in a later stage, can be executed, without the need of additional equity, taking into account the delayed start-up and slower than expected production ramp-up.
 
The Directed Share Issue and use of proceeds
Renewcell intends to, based on the authorization granted by the annual general meeting held on 17 May 2022 and with deviation from the shareholders' preferential right, carry out a directed new issue of shares corresponding to proceeds of approximately SEK 150 million to cover the funding need, towards Swedish and international institutional investors.
 
The proceeds from the contemplated Directed Share Issue will mainly be used according to the funding need as described above. If the proceeds from the Directed Share Issue, after transaction costs, exceeds the total approximate funding need as described above, the surplus will be used for general corporate purposes.
 
The subscription price and the total number of new shares in the Directed Share Issue will be determined through an accelerated bookbuilding procedure, which will begin immediately following this announcement. Should the Board of Directors resolve to carry out the Directed Share Issue, pricing and allocation of shares is expected to take place before the start of trading on Nasdaq First North Premier Growth Market on 28 October 2022. The exact timing of the closing of the bookbuilding, pricing and allocation are at the discretion of Renewcell in consultation with the Managers. The bookbuilding procedure may close earlier or later and may be cancelled at any point in time. Renewcell will announce the outcome by way of a press release after the closing of the bookbuilding procedure.
 
The Company’s largest shareholders, H&M Group and Girincubator AB (via the family affiliated Girindus Investments AB) have indicated interest to participate in the Directed Share Issue.
 
Prior to the Directed Share Issue, the Board of Directors has also considered the possibility to raise the required equity through a rights issue but concluded that a rights issue would be significantly more time-consuming and entail significantly higher costs and increased exposure to potential market volatility compared to the Directed Share Issue. Given the market volatility seen during 2022, that is still ongoing, the Board of Directors has assessed that a rights issue would also require a rather significant underwriting from a guarantor syndicate that would entail additional costs and/or additional dilution depending on the type of remuneration for such underwriting. The more time-consuming rights issue alternative would also further delay the initiation of the commercial start of the Renewcell 1 plant which in turn would lead to a corresponding delay of initiation of revenue generation that would cause a further need for external funding. The Company has concluded that a delayed commercial start is not in the best interest of the shareholders. Unlike a rights issue, the Directed Share Issue can also broaden as well as strengthen the shareholder base and provide the Company with new shareholders, which the Board of Directors considers to be of great benefit to Renewcell.
 
In light of the above, the Board of Directors has made the assessment that a Directed Share Issue with deviation from the shareholders’ preferential rights is the most favourable alternative for Renewcell and in the best interest of all the Company’s shareholders. As the subscription price in the Directed Share Issue will be determined through a bookbuilding procedure at arm’s length, the Board of Directors assesses that the subscription price will reflect current market value and demand.
 
Lock-up
The Company will, subject to customary exemptions and the completion of the Directed Share Issue, undertake, in favour of the Managers, not to issue additional shares for a period of 180 calendar days from the settlement date of the Directed Share Issue.
 
Earlier publication of the interim report Q3 2022
In light of the contemplated Directed Share Issue, Renewcell has today and in conjunction herewith through a separate press release published its report for the third quarter of 2022. The report, which covers the period 1 January to 30 September 2022, has been published today, 27 October 2022, instead of 28 October 2022 as previously communicated.
 
Advisors
In conjunction with the Directed Share Issue, the Company has engaged Nordea as Sole Global Coordinator and Joint Bookrunner and Pareto as Joint Bookrunner. Advokatfirman Vinge KB is legal advisor to the Company and Baker & McKenzie Advokatbyrå KB is legal advisor to the Sole Global Coordinator and Joint Bookrunners.

Datum 2022-10-27, kl 17:31
Källa MFN
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet